ALNY FY 2017 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+90.7% YoY

Gross Profit

$77M85.1% margin

Operating Income

-$500M-556.2% margin

Net Income

-$491M-545.9% margin

EPS (Diluted)

$-5.42

Cash Flow

Operating Cash Flow

-$383M

Free Cash Flow

-$487M

Stock-Based Comp.

$93M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$228M

Stockholders' Equity

$1.8B

Cash & Equivalents

$645M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$47M	+90.7%
Gross Profit	$77M	$47M	+62.3%
Operating Income	-$500M	-$425M	-17.8%
Net Income	-$491M	-$410M	-19.7%